Important COVID-19 Information for Cancer Patients. READ NOW
Now Offering Phone and Video Appointments for Cancer Care
Eric A. Ross, PhD, ScM
About
Assistant Vice President of Biometrics and Information Sciences
Director, Biostatistics and Bioinformatics Facility
Director, Population Studies Facility
Research Professor
TRDG Member:
- Brain Cancer
- Breast Cancer
- Colorectal and SI Cancer
- Esophagus, Pancreas, and Liver Cancer
- Head and Neck Cancer
- Kidney, Bladder, and Prostate Cancer
- Leukemia and MDS
- Lung Cancer and Mesothelioma
- Lymphoma and CLL Cancer
- Melanoma and Skin Cancer
- Ovarian and Gynecologic Cancer
- Sarcoma and GIST Cancer
- Thyroid and Endocrine Cancer
Research Program
Education and Training
Educational Background
- PhD, Statistics, Temple University, 1996
- ScM, Biostatistics, Bloomberg School of Public Health, The Johns Hopkins University, 1984
- BA, Biological Sciences, University of Delaware, 1980
Memberships
- American Statistical Association, member
- International Biometrics Society, member
- American Medical Informatics Association, member
- Society for Clinical Trials, member
Research Profile
Research Program
Research Facility
Research Interests
- Development of new randomized phase II clinical trial designs.
- Application of state of the art statistical approaches to rigorously extend the quantitative interpretation of data.
- Large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.
Lab Overview
Our research focuses on the innovative use of quantitative methods and information technology in cancer research. Our statistical methodology research includes development and application of novel methods for the analysis of correlated failure time and high throughput laboratory data. We are also interested in the creation of new randomized Phase II clinical trial designs that permit early stopping in both patient number and time of initial evaluation. These designs provide for early termination for futility or efficacy, and should be particularly appropriate for studies in patient populations with a high likelihood for rapid disease progression. Our collaborations with numerous investigators conducting clinical, translational, cancer control, epidemiology, and basic science research rigorously extend the quantitative interpretation of results from these disciplines. Our informatics research facilitates cancer investigations by promoting the use of computer-based methods that improve research efficiency and data quality. Special areas of interest include large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.
Lab Staff
Olga Tchuvatkina, MS
Manager of Population Studies Facility
Room: Friends Hall - East Wing
215-214-1494
Christine Huang, MS
Software Architect
Room: Friends Hall - East Wing
215-728-3641
Stanford Taylor, MS
Data Warehouse Architect
Room: Friends Hall - East Wing
215-214-1493
Pawel Przybysz, BS
Programmer Analyst
Room: Friends Hall - East Wing
215-728-2708
Publications
Selected Publications
Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR. Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemporary Clinical Trials Communications, 9:135-42, 2018. PMC5898501
Wagner J, Kline CL, Zhou LL, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 128(6):2325-38, 2018. PubMed
Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR. Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemporary Clinical Trials Communications, 9:135-42, 2018.
Matthew EM, Yang Z, Peri S, Andrake M, Dunbrack R, Ross E, El-Deiry WS. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia (New York, NY), 20(3):244-55, 2018. PMC5849802
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun, 8(1):1772, 2017. PMC5701248
Plimack, ER, Dunbrack, R, Brennan, T, Andrake, M, Zhou, Y, Serebriiskii, I, Wei, Q, Slifker, M, Alpaugh, K, Dulaimi, E, Palma, N, Hoffman-Censits, J, Bilusic, M, Wong, YN, Kutikov, A, Viterbo, R, Greenberg, RE, Chen, D, Lallas, CD, Trabulski, EJ, Yelensky, R, McConkey, D, Miller, VA, Golemis, E, Ross, E. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015; epub ahead of print PubMed
Weinberg DS, Myers RE, Keenan E, Ruth K, Sifri R, Ziring B, Ross E, Manne SL. Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med. 2014 Oct 21;161(8):537-45. PubMed PMID: 25329201; PubMed Central PMCID: PMC4412019. PubMed
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. PubMed PMID: 24821881; PubMed Central PMCID: PMC4050203. PubMed
Min H, Ohira R, Collins MA, Bondy J, Avis NE, Tchuvatkina O, Courtney PK, Moser RP, Shaikh AR, Hesse BW, Cooper M, Reeves D, Lanese B, Helba C, Miller SM, Ross EA. Sharing behavioral data through a grid infrastructure using data standards. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):642-9. PubMed PMID: 24076749; PubMed Central PMCID: PMC4078270. PubMed
Handorf E, Ross EA. Uncertainty in pilot parameter estimates: A comparison of methods to size full trials. Proceedings of the American Statistical Association, Statistics Section; 2013; Toronto, Canada. c2015. PubMed
Bleicher RJ, Ruth K, Sigurdson ER, Ross E, Wong YN, Patel SA, Boraas M, Topham NS, Egleston BL. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012 Dec 20;30(36):4485-92. PubMed PMID: 23169513; PubMed Central PMCID: PMC3518727. PubMed
Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. PubMed PMID: 22011582; PubMed Central PMCID: PMC3223472. PubMed
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7. PubMed PMID: 19162309; PubMed Central PMCID: PMC2741166. PubMed
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59. PubMed PMID: 16333030. PubMed
Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther. 2004 Dec;3(12):1313-21. PubMed PMID: 15662135. PubMed
Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76. PubMed PMID: 11927497. PubMed
Additional Publications
Contact Information
Lab Phone: 215-728-2891
Fax: 215-728-2553
Office: R383
Eric.Ross@fccc.edu
Contact Information
Lab Phone: 215-728-2891
Fax: 215-728-2553
Office: R383
Eric.Ross@fccc.edu
Assistant Vice President of Biometrics and Information Sciences
Director, Biostatistics and Bioinformatics Facility
Director, Population Studies Facility
Research Professor
TRDG Member:
- Brain Cancer
- Breast Cancer
- Colorectal and SI Cancer
- Esophagus, Pancreas, and Liver Cancer
- Head and Neck Cancer
- Kidney, Bladder, and Prostate Cancer
- Leukemia and MDS
- Lung Cancer and Mesothelioma
- Lymphoma and CLL Cancer
- Melanoma and Skin Cancer
- Ovarian and Gynecologic Cancer
- Sarcoma and GIST Cancer
- Thyroid and Endocrine Cancer
Research Program
Education
Educational Background
- PhD, Statistics, Temple University, 1996
- ScM, Biostatistics, Bloomberg School of Public Health, The Johns Hopkins University, 1984
- BA, Biological Sciences, University of Delaware, 1980
Memberships
- American Statistical Association, member
- International Biometrics Society, member
- American Medical Informatics Association, member
- Society for Clinical Trials, member
Research Profile
Research Facility
Research Interests
- Development of new randomized phase II clinical trial designs.
- Application of state of the art statistical approaches to rigorously extend the quantitative interpretation of data.
- Large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.
Lab Overview
Our research focuses on the innovative use of quantitative methods and information technology in cancer research. Our statistical methodology research includes development and application of novel methods for the analysis of correlated failure time and high throughput laboratory data. We are also interested in the creation of new randomized Phase II clinical trial designs that permit early stopping in both patient number and time of initial evaluation. These designs provide for early termination for futility or efficacy, and should be particularly appropriate for studies in patient populations with a high likelihood for rapid disease progression. Our collaborations with numerous investigators conducting clinical, translational, cancer control, epidemiology, and basic science research rigorously extend the quantitative interpretation of results from these disciplines. Our informatics research facilitates cancer investigations by promoting the use of computer-based methods that improve research efficiency and data quality. Special areas of interest include large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.
Lab Staff
Olga Tchuvatkina, MS
Manager of Population Studies Facility
Room: Friends Hall - East Wing
215-214-1494
Christine Huang, MS
Software Architect
Room: Friends Hall - East Wing
215-728-3641
Stanford Taylor, MS
Data Warehouse Architect
Room: Friends Hall - East Wing
215-214-1493
Pawel Przybysz, BS
Programmer Analyst
Room: Friends Hall - East Wing
215-728-2708
Publications
Selected Publications
Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR. Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemporary Clinical Trials Communications, 9:135-42, 2018. PMC5898501
Wagner J, Kline CL, Zhou LL, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 128(6):2325-38, 2018. PubMed
Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR. Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemporary Clinical Trials Communications, 9:135-42, 2018.
Matthew EM, Yang Z, Peri S, Andrake M, Dunbrack R, Ross E, El-Deiry WS. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia (New York, NY), 20(3):244-55, 2018. PMC5849802
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun, 8(1):1772, 2017. PMC5701248
Plimack, ER, Dunbrack, R, Brennan, T, Andrake, M, Zhou, Y, Serebriiskii, I, Wei, Q, Slifker, M, Alpaugh, K, Dulaimi, E, Palma, N, Hoffman-Censits, J, Bilusic, M, Wong, YN, Kutikov, A, Viterbo, R, Greenberg, RE, Chen, D, Lallas, CD, Trabulski, EJ, Yelensky, R, McConkey, D, Miller, VA, Golemis, E, Ross, E. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015; epub ahead of print PubMed
Weinberg DS, Myers RE, Keenan E, Ruth K, Sifri R, Ziring B, Ross E, Manne SL. Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med. 2014 Oct 21;161(8):537-45. PubMed PMID: 25329201; PubMed Central PMCID: PMC4412019. PubMed
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. PubMed PMID: 24821881; PubMed Central PMCID: PMC4050203. PubMed
Min H, Ohira R, Collins MA, Bondy J, Avis NE, Tchuvatkina O, Courtney PK, Moser RP, Shaikh AR, Hesse BW, Cooper M, Reeves D, Lanese B, Helba C, Miller SM, Ross EA. Sharing behavioral data through a grid infrastructure using data standards. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):642-9. PubMed PMID: 24076749; PubMed Central PMCID: PMC4078270. PubMed
Handorf E, Ross EA. Uncertainty in pilot parameter estimates: A comparison of methods to size full trials. Proceedings of the American Statistical Association, Statistics Section; 2013; Toronto, Canada. c2015. PubMed
Bleicher RJ, Ruth K, Sigurdson ER, Ross E, Wong YN, Patel SA, Boraas M, Topham NS, Egleston BL. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012 Dec 20;30(36):4485-92. PubMed PMID: 23169513; PubMed Central PMCID: PMC3518727. PubMed
Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. PubMed PMID: 22011582; PubMed Central PMCID: PMC3223472. PubMed
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7. PubMed PMID: 19162309; PubMed Central PMCID: PMC2741166. PubMed
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59. PubMed PMID: 16333030. PubMed
Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther. 2004 Dec;3(12):1313-21. PubMed PMID: 15662135. PubMed
Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76. PubMed PMID: 11927497. PubMed
Additional Publications
Related Articles
